. A.Belgorosky and M.A.Rivarola.End o c r i n o l o g i a , H o s p l t a l dc P e r i r a t r i a Gorrahan, Buenos Alres, Argeritrna A s s o c i a t i o n o f d e l a y e d p u b e r t y and low serum IGF-I 1 s observer1 ~n GH deficiency and c h r o n l c m a l n u t r i t i o n , w h i l e advanced c e n t r a l pubert y and h i g h IGF-I is seen ~n c h l l d r e n a f t e r l o n g t i m e e x p o s u r e t o h i g h l e v e l s o f s e x horrnones(Sti). Whlle some workers have r e p o r t e d a d e c r e a s e o f serum IGF-I d u r l n g t h e r a p y o f p r e c o c i o u s p u b e r t y ( P P ) w i t h GnRHa, o t h e r s have shown no change. We have s t u d l e d 7 c h i l d r e n w l t h PP, 4 w i t h c e n t r a l PP(2 boys aged 3 . 5 and 7 . 5 y , 2 g i r l s aged 6.1 and 5.6 y ) and 3 w i t h s i m p l e v l r l l l z l n g CAH (meanlSD a g e 5 . 7~2 . 3 , bone a g e 12.9+1.2 y ) , b a t h b e f o r e and 2 t o 7 months a f t e r SH suppressLon (StiS) w i t h c l t h c r l o n g a c t i n g Gnnlia o r hydrocortisone. Serum IGF-I, LH, FSH, t e s t o s t c r o n c (TI and e s t r a d i o l (E ) were measured by RIA. k GnRH t e s t was c a r r i e d o u t i n t h e 3 p a t l e n t 2 with CAI+. Berore SHS, serum IGF-I and T ( b o y s ) o r E (girls) were 1.5210.0 U/ml ( 5 t o Il-yo l d normal : 0.7210.0) and 1 $ . 7~8 . 6 nmal/L or 230 pmol/L, r e s p e c t l v e l y (meantso o r mean o f duplicate). A f t e r SIIS, v a l u c s ' w e r e 1.78+0.92 and 0.93+0.14 o r 10.5. IGF-I d i d n o t d e c r e a s e i n any p a t i e n t , while Sli d e c r e a s e d I n a l l o f Lhcm. Maxroal LII and FSil r e s p o n s e s t o Gnllil i n CAH were l . 6 0 t l . 1 and 0 . 8 8 + 0 . 5 4 b e f o r e SHS, and 9 . 2 7 t 2 . 2 5 and 6 . 4 6 + 2 . 4 5 U/L 2 t o 72 months a f t e r StlS, r e s p e c t l v e l y . ~e s t ; c u l a r . e n l a r g e m e n t and c l i n i c a l e v r d e n c e of c e n t r a l PP developed ~n CAH p a t i e n t s a f t e r SHS. I t is concluded t h a t a f t e r SHS t o @ r e p u b e r t a l v a l u e s , serum IGF-I remains h i g h I n e l t h e r c e n t r a l PP o r CAH, suggesting t h a t SH induce a m a t u r a t i o n a l change i n IGF-I v a l u e s . S l n c e a f t e r StlS i n CAtI, t h e GnRH t e s t a c q u i r e s a p u b e r t a l p a t t e r n o f r e s p o n s e , IGF-I mlaht be 1"-volved i n t h e p r o c e s s o f maturation o f t h e g o n a d o s t a t . Depanmenl ol i'edlalrics. 'lohoku Univun~tk. Scllool of hlcdl;lne. Scnda~. Jao~n LHRH analogue therapy has been eslirnitrd as useful for suppnsr~ng s&ondq sexual development in c a w of recoclous pubeny and Ir expected to Improve final he~eht. We studied chances in tEe n~tuitarv and cun:~dxl f~ncrmns after crcsnrinn of underwent ubenal dcvelo mcni ~n d exl~ib~lcd 3ccclur;11ion of h i i c n1jturstl~)n ; l~r~r~ a GI1 sup trnent for G l l ScfiLiency or thort,staturc w~thout GIID, ucre treated witk LHRHa. 8~ uas ~niected sukuunmuslv 4.6 urnes 3 ueek .~t 3 donee of (1 541 611 k r / u A andB; LHRHa, 30-60 pg/ml, was administered via a s u b c u~n~o~s injeitioi LTery 4 weeks. Chan es In secondary sexual characteristics, height velocity, bone age height SDS for%one age, serum estradiol, serum gonadotropins and IGF-1 were observed tn all patients, and serum GH was measured in grou A Height velccit /ABA and ABAJACA were calculated in m o w B. <Resulls> A: Ater cessation of L&RH~ -~ treatment, secondary sexual charcten'stics began to progress within 6months, and E2 and eak L H were elevated to the pubertal level within one year. Improvement of height ~D S for B A and increase of height velocity continued at least 6 months after the off-therapy. B; After LHRHa treatment, secondary sexual characteristics were attenuated, acceleration of bone maturation was suppressed and hormonal parameters decreased to the ~re~ubertal ranee in all cases. Heieht SDS fnr l3A ~r n w r h velocity/lDA and A~A I A C A Mere ail improved by LH~tl;ue31~~n1 -<Con;l&:on>
o l d normal : 0.7210.0) and 1 $ . 7~8 . 6 nmal/L or 230 pmol/L, r e s p e c t l v e l y (meantso o r mean o f duplicate). A f t e r SIIS, v a l u c s ' w e r e 1.78+0.92 and 0.93+0.14 o r 10.5. IGF-I d i d n o t d e c r e a s e i n any p a t i e n t , while Sli d e c r e a s e d I n a l l o f Lhcm. Maxroal LII and FSil r e s p o n s e s t o Gnllil i n CAH were l . 6 0 t l . 1 and 0 . 8 8 + 0 . 5 4 b e f o r e SHS, and 9 . 2 7 t 2 . 2 5 and 6 . 4 6 + 2 . 4 5 U/L 2 t o 72 months a f t e r StlS, r e s p e c t l v e l y . ~e s t ; c u l a r . e n l a r g e m e n t and c l i n i c a l e v r d e n c e of c e n t r a l PP developed ~n CAH p a t i e n t s a f t e r SHS. I t is concluded t h a t a f t e r SHS t o @ r e p u b e r t a l v a l u e s , serum IGF-I remains h i g h I n e l t h e r c e n t r a l PP o r CAH, suggesting t h a t SH induce a m a t u r a t i o n a l change i n IGF-I v a l u e s . S l n c e a f t e r StlS i n CAtI, t h e GnRH t e s t a c q u i r e s a p u b e r t a l p a t t e r n o f r e s p o n s e , IGF-I mlaht be 1"-volved i n t h e p r o c e s s o f maturation o f t h e g o n a d o s t a t .
EFFECT OF A LONG ACTlKG LIIRH ANALOGUE AND G t l ON 'I'HE SUPPRESSION 01' SECOSDARY SEXC'AL I)EVELOP3tEfi'f ASD FISAI.
Depanmenl ol i'edlalrics. 'lohoku Univun~tk. Scllool of hlcdl;lne. Scnda~. Jao~n LHRH analogue therapy has been eslirnitrd as useful for suppnsr~ng s&ondq sexual development in c a w of recoclous pubeny and Ir expected to Improve final he~eht. We studied chances in tEe n~tuitarv and cun:~dxl f~ncrmns after crcsnrinn of underwent ubenal dcvelo mcni ~n d exl~ib~lcd 3ccclur;11ion of h i i c n1jturstl~)n ; l~r~r~ a GI1 sup trnent for G l l ScfiLiency or thort,staturc w~thout GIID, ucre treated witk LHRHa. 8~ uas ~niected sukuunmuslv 4.6 urnes 3 ueek .~t 3 donee of (1 541 611 k r / u A andB; LHRHa, 30-60 pg/ml, was administered via a s u b c u~n~o~s injeitioi LTery 4 weeks. Chan es In secondary sexual characteristics, height velocity, bone age height SDS for%one age, serum estradiol, serum gonadotropins and IGF-1 were observed tn all patients, and serum GH was measured in grou A Height velccit /ABA and ABAJACA were calculated in m o w B. <Resulls> A: Ater cessation of L&RH~ -~ treatment, secondary sexual charcten'stics began to progress within 6months, and E2 and eak L H were elevated to the pubertal level within one year. Improvement of height ~D S for B A and increase of height velocity continued at least 6 months after the off-therapy. B; After LHRHa treatment, secondary sexual characteristics were attenuated, acceleration of bone maturation was suppressed and hormonal parameters decreased to the ~re~ubertal ranee in all cases. Heieht SDS fnr l3A ~r n w r h velocity/lDA and A~A I A C A Mere ail improved by LH~tl;ue31~~n1 -<Con;l&:on>
The suppression of pubert~l bone mxturstlon by L I I R I~J ~3 s s~gn~ficsnt On the other hand, second3ry sexual ch;~r;~ctc.rist~cs Jc\,clopc.J prornp~l! ~f~e r the cessation of LHRHa treatment. This data suggests the possibiliiy of im-rovin final height without any side effects by a combinat~on therapy consisting of d;I a n d k~~a .
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PRECOCIOUS PUBERTY IN NEUROFlBROMATOSlS TYPE 1 (NF-1).
R. Habiby, B.L. Silverman. R. Listernick, J. Charrow. Department of Pediatrics, Northwestern University, Chicago, IL 60614, USA.
Precocious puberty (PP) has been reported in children with NF-1. primarily in the presence of optic pathway tumors (OPT). We evaluated 201 children with NF-1, 157 of whom had CNS imaging; 31 had OPT. Of these, 19 were 2-10 yrs old. Four of these children had PP, while no child without an OPT had clinical PP. We conducted a prospective case control study to investigate the effect of OPT on the maturation of the hypothalamic-pituitary-gonadal axis in children with NF-1, and the association between NF-1 and PP in the absence of OPT. We enrolled 24 prepubertal children, 2-10 yrs old, with NF-1, 12 with OPT and 12 without OPT, matched for sex and age. We measured height. weight, parental heights, bone age, and the LH and FSH response to LHRH. A 6 cm difference in height was found between the group with OPT 117.423.9 (MEANt-SE) and without OPT 11 1 5k4.0. (p=0.15). Height Zscores were higher in children with OPT (0.12+0 39 vs -1.07ir0.35,p=O 02).
Bone age minus chronological age was also higher in the glioma group (0.0820.37 yrs vs -0.65k0.35, p=0.08). In response to injected LHRH 100vg, there was a greater rise in LH in the group with OPT (p=0.06). FSH responses were identical. All 4 pubertal responses (peak LH>15mlU/ml) occurred in children with OPT (p<0.05). Three of these children had lesions confined to the intraorbital portion of the optic nerve. We conclude: 1) PP occurred in NF-1 only in the presence of OPT. 2) accelerated growlh was present in the children with OPT. consistent with earlv oubertv. 31 contrarv to expectat ons, a pLoefta respcnse to _nl<ti nas ev.ien! n cn.arbn n :*i ' tJmors remo!e liom tne n\r>o'r.aan-s anc 41 he nave .oen I co a subpopulation who provide a unique opportunity to prospectively investigate the pathogenesis of PP. In our ongoing sludies, 60 girls with CPP have been evaluated at 6-12111 intervals for 2 12 months following the discontinuation of GnRHa. All received daily sc injections of eitlier deslorelin or histrelin for 3.8 * 0.2 years (range 2.0-7.7). Of these 60 girls, 36 have attained their final height (at FHT; GV < 2 cmlyear. TW BA = 16 years), while the remainder have some residual growth potential (near FHT). In bolh subsets, the latest measured HT, while remaining 7.1 * 1.0 cnl below the genetic target HT, significantly exceeded the Bayley-Pinneau prediclioli prior to GnRHa administrat~on (*, p = 0,0001). A single girl w~th a p~e-GnRlla BA < 10 yrs has reached her FHT, while such patlents comprise 34% of our total CPP female population. Since changes in predicted HT during G1rR11a ad~ninistralion correlate significantly with prelherapy CA and BA, we must slill await the FIiT outcomes in young patients enrolled early in puberty to judge comprehensively the impact of gonadal sex steroid suppression on FHT in patients with CPP.
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FINAL HEIGHTS FOLLOWING GIIRI~~-INDUCED PITUITARY-GONADAL SUPPRESSION I N GIRLS WITH CENTRAL PRECOCIOUS PUBERTY (CPP
Pre-CIIRII~ DIC GnRHa Pre-C11Rlla LATEST IFMA. oy AP every child ha;> 2 MI/rnl values. B FSH levels was detectable in a l l the groups and was significantly ( P C 0.03) greater i n F than in M in W. Upon GnRH test, the distinction between the groJps was better. P LH x + O S W: 7.93 + 0.94 vs EP:
10.34 r 4.93 (P40.0331) vs W : 21.8 + 8.98 mUl/ml (pCO.OW1). Nc?taticatly difference was found between I RMR or I W . Ail of the W F and M had a ratio P LH to P FSH which was less than 1 and increased slgnificantl; with pubertal onset. In CP before the appearance of pubertal signs a t BR 11.94 + 0.47 y the LH response to the' Gn RH was 10.40 r 4.60 vs 2.61 t 2.14 mljl/ml (p LO.O~XJI) in h. L H responses did not overlap in eTther grwp. W Z conclude, that the test of Gn RH using gonadotropin ultrasensitive assay i s useful in identifying the onset of puberty, and in the discri mination of W fron M. 
510
